Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 1.00 |
| ▸ | ADH1B | P00325 | 4/20 | 1.00 |
| ▸ | ADH1A | P07327 | 4/20 | 1.00 |
| ▸ | ADH7 | P40394 | 4/20 | 1.00 |
| ▸ | ADH1C | P00326 | 3/20 | 1.00 |
| ▸ | ADH4 | P08319 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303653 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL145544 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL9660807 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL9661679 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL9661848 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL58363 | 1.00 | — | — | |
| SCHEMBL9658779 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL4879688 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL305123 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL149028 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-8093422-B2 | Method for deuteration of an aromatic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-7517990-B2 | Method for deuteration of a heterocyclic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20070255064-A1 | Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1786780-A1 | IMIDAZOLIUM-METHYL SULFITES FOR USE AS STARTING COMPOUNDS FOR PRODUCING IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| EP-1707548-A1 | METHOD OF DEUTERATION USING MIXED CATALYST | Wako Pure Chemical Industries, Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20060116535-A1 | Method of deuteration | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-5047540-A | Platelet Activating Factor Antagonists and Antitumor Agents | SHIONOGI & CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0321296-A1 | Lipid derivatives their preparation and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
| EP-0088386-B1 | NEW 1,4-DIAMINOCYCLITOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| US-4504472-A | MICROBIOCIDES, IMMUNOSTIMULANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| EP-0088386-A1 | New 1,4-diaminocyclitol derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070255064-A1 | Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids | CBR3, SCO2, PRMT5 | EPHX1 3935/4885ADH1B 2812/4885ADH1A 3298/4885 |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | HDHD5, DHX35, HRH3 | EPHX1 2426/4885ADH1B 502/4885ADH1A 1333/4885 |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | HRH3, HRH4, AHR | EPHX1 2302/4885ADH1B 501/4885ADH1A 823/4885 |
| US-20060116535-A1 | Method of deuteration | ARL1, IDH2, IDH3A | EPHX1 2129/4885ADH1B 477/4885ADH1A 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.